FAQ Directory: HEDIS

Filter Results

Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Print
Print this page.
Print this page.
Share
Share this page with a friend or colleague by Email.
We do not share your information with third parties.

You are viewing a single FAQ from your previous search. Clear Search

11.14.2014 Osteoporosis Management in Women Who Had a Fracture CMS required the use of temporary HCPCS code Q2051 (Injection, Zoledronic acid, 1 mg) from July 1–December 31, 2013. This code is not included in the Osteoporosis Medications Value Set. May organizations map this code and use it for HEDIS 2015 reporting?

Yes. Organizations may map Q2051 to J3489 (which is included in the Osteoporosis Medications Value Set and is for the same medication and dose) for HEDIS 2015 reporting. Auditors review mapped codes as part of the HEDIS Compliance Audit.

HEDIS 2015